SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Morgan Stanley Says Moderna's INT Outlook Strengthens on Melanoma Data

Morgan Stanley said Moderna's phase 3 adjuvant melanoma data strengthen its outlook for INT.

MRNA

Related stories